Commonwealth Equity Services’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.22M | Buy |
49,381
+33,301
| +207% | +$793K | ﹤0.01% | 2432 |
|
|
2025
Q4 | $375K | Buy |
16,080
+927
| +6% | +$20.6K | ﹤0.01% | 3451 |
|
|
2025
Q3 | $299K | Sell |
15,153
-22,549
| -60% | -$464K | ﹤0.01% | 3643 |
|
|
2025
Q2 | $818K | Sell |
37,702
-3,873
| -9% | -$91.4K | ﹤0.01% | 2744 |
|
|
2025
Q1 | $1.01M | Buy |
41,575
+2,244
| +6% | +$50.5K | ﹤0.01% | 2447 |
|
|
2024
Q4 | $821K | Buy |
39,331
+22,455
| +133% | +$482K | ﹤0.01% | 2550 |
|
|
2024
Q3 | $335K | Sell |
16,876
-2,023
| -11% | -$37.5K | ﹤0.01% | 3253 |
|
|
2024
Q2 | $293K | Sell |
18,899
-684
| -3% | -$10.6K | ﹤0.01% | 3313 |
|
|
2024
Q1 | $312K | Sell |
19,583
-638
| -3% | -$9.61K | ﹤0.01% | 3238 |
|
|
2023
Q4 | $340K | Buy |
20,221
+3,041
| +18% | +$41.6K | ﹤0.01% | 3065 |
|
|
2023
Q3 | $201K | Sell |
17,180
-6,824
| -28% | -$91.3K | ﹤0.01% | 3375 |
|
|
2023
Q2 | $323K | Buy |
24,004
+3,360
| +16% | +$48.4K | ﹤0.01% | 2984 |
|
|
2023
Q1 | $342 | Buy |
20,644
+408
| +2% | +$6.73K | ﹤0.01% | 2845 |
|
|
2022
Q4 | $376K | Buy |
20,236
+4,318
| +27% | +$66.5K | ﹤0.01% | 2702 |
|
|
2022
Q3 | $204K | Buy |
15,918
+2,233
| +16% | +$26.5K | ﹤0.01% | 3155 |
|
|
2022
Q2 | $95K | Buy |
13,685
+2,885
| +27% | +$21.2K | ﹤0.01% | 3382 |
|
|
2022
Q1 | $89K | Sell |
10,800
-2,055
| -16% | -$14.5K | ﹤0.01% | 3514 |
|
|
2021
Q4 | $87K | Buy |
12,855
+641
| +5% | +$4.21K | ﹤0.01% | 3483 |
|
|
2021
Q3 | $64K | Buy |
12,214
+1,158
| +10% | +$6.33K | ﹤0.01% | 3475 |
|
|
2021
Q2 | $63K | Hold |
11,056
| – | – | ﹤0.01% | 3447 |
|
|
2021
Q1 | $50K | Sell |
11,056
-1,259
| -10% | -$5K | ﹤0.01% | 3335 |
|
|
2020
Q4 | $41K | Sell |
12,315
-1,000
| -8% | -$3.36K | ﹤0.01% | 3142 |
|
|
2020
Q3 | $39K | Hold |
13,315
| – | – | ﹤0.01% | 2974 |
|
|
2020
Q2 | $61K | Sell |
13,315
-3,000
| -18% | -$13.5K | ﹤0.01% | 2830 |
|
|
2020
Q1 | $62K | Hold |
16,315
| – | – | ﹤0.01% | 2650 |
|
|
2019
Q4 | $61K | Hold |
16,315
| – | – | ﹤0.01% | 2785 |
|
|
2019
Q3 | $86K | Sell |
16,315
-1,000
| -6% | -$5.33K | ﹤0.01% | 2695 |
|
|
2019
Q2 | $66K | Sell |
17,315
-11,500
| -40% | -$49.7K | ﹤0.01% | 2672 |
|
|
2019
Q1 | $146K | Buy |
28,815
+1,000
| +4% | +$2.94K | ﹤0.01% | 2537 |
|
|
2018
Q4 | $53K | Buy |
27,815
+3,500
| +14% | +$10K | ﹤0.01% | 2561 |
|
|
2018
Q3 | $91K | Sell |
24,315
-500
| -2% | -$1.57K | ﹤0.01% | 2648 |
|
|
2018
Q2 | $77K | Hold |
24,815
| – | – | ﹤0.01% | 2625 |
|
|
2018
Q1 | $59K | Hold |
24,815
| – | – | ﹤0.01% | 2586 |
|
|
2017
Q4 | $97K | Buy |
24,815
+1,000
| +4% | +$3.3K | ﹤0.01% | 2516 |
|
|
2017
Q3 | $60K | Hold |
23,815
| – | – | ﹤0.01% | 2458 |
|
|
2017
Q2 | $66K | Sell |
23,815
-275
| -1% | -$574 | ﹤0.01% | 2401 |
|
|
2017
Q1 | $47K | Buy |
24,090
+90
| +0.4% | +$115 | ﹤0.01% | 2329 |
|
|
2016
Q4 | $25K | Hold |
24,000
| – | – | ﹤0.01% | 2274 |
|
|
2016
Q3 | $26K | Sell |
24,000
-1,500
| -6% | -$1.35K | ﹤0.01% | 2203 |
|
|
2016
Q2 | $18K | Sell |
25,500
-4,053
| -14% | -$3.27K | ﹤0.01% | 2205 |
|
|
2016
Q1 | $35K | Hold |
29,553
| – | – | ﹤0.01% | 2149 |
|
|
2015
Q4 | $72K | Buy |
29,553
+1,053
| +4% | +$3.02K | ﹤0.01% | 2067 |
|
|
2015
Q3 | $86K | Sell |
28,500
-6,600
| -19% | -$28.5K | ﹤0.01% | 2000 |
|
|
2015
Q2 | $145K | Buy |
35,100
+24,100
| +219% | +$96.1K | ﹤0.01% | 2011 |
|
|
2015
Q1 | $48K | Buy |
+11,000
| New | +$39.7K | ﹤0.01% | 2118 |
|
Other funds holding CPRX
VCM
DM
VPM
Commonwealth Equity Services's CPRX Position: Q1 2026 in Review
Commonwealth Equity Services increased its Catalyst Pharmaceutical (CPRX) stake by 207% in Q1 2026, buying an estimated $793K and bringing the position to 49,381 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #2432.
Commonwealth Equity Services first reported a position in CPRX in Q1 2015 and has held it in 45 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- Commonwealth Equity Services held 49,381 shares of Catalyst Pharmaceutical worth $1.22M as of Q1 2026.
- Commonwealth Equity Services bought 33,301 Catalyst Pharmaceutical shares in Q1 2026, an estimated $793K.
- Catalyst Pharmaceutical made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q1 2026, its #2432 holding.
- Commonwealth Equity Services first reported a position in Catalyst Pharmaceutical in Q1 2015 and has held it in 45 quarters since.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.